Skip to main content
Premium Trial:

Request an Annual Quote

Douglas Fambrough, Loretta Itri

Premium
Douglas Fambrough, a principal at Boston-based Oxford Bioscience Partners, has been appointed to the audit committee of Solexa.
 
Fambrough currently sits on the board of Sirna Therapeutics. He holds a PhD in genetics from the University of California, Berkeley.
 

 
Pharmacyclics said that board member Loretta Itri will not stand for re-election at the company’s annual meeting in December.
According to the firm, she is leaving the board in order to focus on her duties as president and chief medical officer of Genta.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.